You are too kind. There goes my streak of being within 0.1M of revenue #s as I guesstimated the previous 2 Qtrs. Got overly excited about Evomela revenues. A month ago I was guesstimating Evomela sales of between 9 and 10M but got carried away w thinking the rise in the stock was about fantastic #s. Was surprised w Fusilev being as low as it was since Sagent was reporting a shortage of leucovorin in Dec. So it seems nothing will help Fusivev in the future especially w TEVA introducing product recently. Still, revenues beat Yahoo analyst estimates by $4M which is something. Haven't listened to the CC yet and will attempt to do so now.
News 
Market Data 
Discover 
